The global postoperative nausea and vomiting (PONV) management market garnered a market value of USD 1.04 Billion in 2022 and is expected to accumulate a market value of USD 3.9 Billion by registering a CAGR of 12.8% in the forecast period 2023 to 2033.
Growth of the postoperative nausea and vomiting (PONV) management market can be attributed to increasing number of surgeries being performed and the growing awareness of the importance of managing PONV for patient comfort and safety. The market for postoperative nausea and vomiting (PONV) management registered a CAGR of 7.4% in the historical period 2018 to 2022
Postoperative nausea and vomiting (PONV) management refers to the various strategies and interventions used to prevent or treat nausea and vomiting in patients after surgery. PONV is a common side effect of anesthesia and surgery, affecting up to 80% of patients in some cases. It can cause discomfort, dehydration, electrolyte imbalances, and delayed recovery.
PONV management typically involves a combination of pharmacological and non-pharmacological interventions, such as antiemetic medications, IV fluids, and the use of acupressure or acupuncture. Effective PONV management is essential for patient comfort and recovery after surgery, and can also help prevent complications such as aspiration pneumonia and wound dehiscence.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 1.17 Billion |
| Anticipated Forecast Value (2033) | USD 3.9 Billion |
| Projected Growth Rate (2023 to 2033) | 12.8% CAGR |
According to market research and competitive intelligence provider Future Market Insights- the market for Postoperative nausea and vomiting (PONV) management reflected a value of 7.4% during the historical period, 2018 to 2022.
The PONV management market has been growing steadily in recent years due to several factors, including an increasing number of surgeries being performed worldwide, growing awareness of the importance of PONV management for patient comfort and safety, and the development of new and effective antiemetic medications.
Several factors are driving the growth of the PONV management market, including the increasing prevalence of PONV, the development of new and effective antiemetic medications, and the adoption of non-pharmacological approaches to PONV management.
Thus, the market for postoperative nausea and vomiting (PONV) management is expected to register a CAGR of 12.8% in the forecast period 2023 to 2033.
Increasing number of surgeries driving growth of PONV market
The growing number of surgeries being performed globally is a key driver of the PONV management market. As the number of surgeries increases, the incidence of PONV also rises, leading to a greater demand for effective PONV management solutions.
The development of new and more effective antiemetic medications is another important driver of the PONV management market. These medications can provide better control of PONV symptoms, resulting in improved patient outcomes and satisfaction.
Healthcare providers are increasingly aware of the importance of managing PONV for patient comfort and safety. This has led to greater adoption of PONV management protocols and the use of a range of pharmacological and non-pharmacological interventions.
The development of new technologies, such as electronic stimulation devices, has expanded the range of PONV management solutions available to healthcare providers. These technologies provide non-pharmacological options that can be used in conjunction with antiemetic medications to improve PONV management outcomes.
Pharmacological Interventions
Antiemetic Medications: Antiemetic medications are the most commonly used pharmacological intervention for PONV management. These medications work by blocking specific receptors in the brain that are responsible for inducing nausea and vomiting. Some of the commonly used antiemetic medications include ondansetron, dexamethasone, and metoclopramide.
Anesthetic Technique: The choice of anesthetic technique used during surgery can also impact the incidence of PONV. Regional anesthesia, such as spinal or epidural anesthesia, has been shown to be associated with a lower incidence of PONV compared to general anesthesia.
Non-Pharmacological Interventions
Acupuncture: Acupuncture involves the insertion of fine needles into specific points on the body to stimulate nerve pathways and promote healing. It has been shown to be effective in reducing the incidence of PONV.
Acupressure: Acupressure involves the application of pressure to specific points on the body to stimulate nerve pathways and promote healing. It has been shown to be effective in reducing the incidence of PONV.
Transcutaneous Electrical Nerve Stimulation (TENS): TENS involves the use of small electrical currents to stimulate nerve pathways and promote healing. It has been shown to be effective in reducing the incidence of PONV.
Side effects of antiemetics and expensive nature of PONV management hampering market growth
Patients vary widely in their susceptibility to PONV, and it can be difficult to predict who will experience it. This variability makes it challenging for healthcare providers to tailor treatments to individual patients.
Antiemetic medications are commonly used to manage PONV, but they can have side effects such as sedation, dizziness, and dry mouth. These side effects can be particularly problematic for patients who are already recovering from surgery.
Antiemetic medications can be expensive, and their cost can be a barrier to access for some patients. This can limit the ability of healthcare providers to provide effective PONV management. There is a lack of standardization in the management of PONV, with different healthcare providers using different protocols and medications. This can lead to inconsistency in care and can make it difficult to compare outcomes across different facilities.
Prevention is key to managing PONV, but it can be challenging to identify patients who are at high risk and to implement appropriate preventive measures. This can result in a higher incidence of PONV and increased costs associated with treatment. Some patients and healthcare providers may not be aware of the risks associated with PONV, or may not take it seriously enough. This can lead to inadequate management and can result in unnecessary suffering for patients.
Increasing number of surgeries performed in the region boosting market growth
The North America postoperative nausea and vomiting (PONV) management market is a significant segment of the global PONV management market. North America comprises of developed countries such as the United States and Canada, which have well-established healthcare systems and advanced medical technologies.
The market growth can be attributed to factors such as the increasing number of surgical procedures, rising geriatric population, and the growing prevalence of PONV. The United States dominates the North America PONV management market due to the presence of a large number of hospitals, advanced healthcare infrastructure, and high healthcare expenditure.
According to the Centers for Disease Control and Prevention (CDC), there were around 50 Billion surgeries performed in the United States in 2017, which is expected to increase in the coming years. This high number of surgeries creates a significant demand for PONV management products and services.
The major players in the North America PONV management market include Acacia Pharma Group plc, Heron Therapeutics, Inc., Merck & Co., Inc., Eisai Co., Ltd., and GlaxoSmithKline plc. These companies are focused on developing innovative products and technologies to improve PONV management, which is expected to drive market growth in the region. Thus, North America is expected to possess 47% market share for PONV management market in 2023.
Technological advancements creating lucrative opportunities for PONV management in Europe
PONV is a common complication of surgery and affects a significant proportion of patients. According to a study published in the European Journal of Anaesthesiology, the incidence of PONV in Europe ranges from 10% to 80% depending on the type of surgery and patient characteristics. The increasing prevalence of PONV is driving the demand for effective PONV management products and services.
The number of surgical procedures performed in Europe is increasing, driven by factors such as the aging population, changing lifestyles, and advancements in medical technology. This creates a significant demand for PONV management products and services.
There have been significant technological advancements in the field of PONV management, such as the development of new antiemetic drugs and the use of non-pharmacological interventions such as acupuncture and acupressure. These advancements are improving the effectiveness of PONV management and are driving market growth.
Governments in Europe are taking initiatives to improve the quality of healthcare and reduce the burden of postoperative complications such as PONV. For example, the European Society of Anaesthesiology has published guidelines for the management of PONV, which are expected to improve the quality of care and drive market growth.
There is growing awareness among patients and healthcare providers about the risks associated with PONV and the importance of effective management. This is driving demand for PONV management products and services. Thus, Europe is expected to possess 43% market share for PONV management market in 2023.
Timely administration favoring growth of hospital pharmacies for PONV management
Hospital pharmacies have direct access to a wide range of antiemetic medications that are commonly used for PONV management. This allows healthcare providers to quickly obtain the appropriate medications for patients who are experiencing PONV.
Hospital pharmacists are highly trained professionals who have a thorough understanding of medication management, including the appropriate use of antiemetics. They can provide guidance on medication selection, dosing, and potential drug interactions, which is essential for effective PONV management.
PONV can occur rapidly and may require immediate intervention. Hospital pharmacies are often located within the hospital or adjacent to the surgical suite, which allows for timely administration of antiemetic medications as needed. In addition to medications, hospital pharmacies may have access to specialized equipment such as intravenous pumps, which can be used for the administration of antiemetic medications.
Compliance with regulations: Hospital pharmacies are subject to strict regulatory requirements, which ensures that medications are stored, dispensed, and administered in a safe and appropriate manner. This is particularly important for PONV management, as many antiemetic medications have the potential for adverse effects. Thus, hospital pharmacies are expected to possess 49% market share for PONV management market in 2023.
Key players in the postoperative nausea and vomiting (PONV) management market are Acacia Pharma, Hoffmann-La Roche AG, Novartis AG, Ani Pharmaceuticals, Inc, Camurus AB, Sanofi S.A., Helsinn Holding S.A., Eisai Corporation, Merck and Co., GlaxoSmithKline Corporation
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 1.17 Billion |
| Market Value in 2033 | USD 3.9 Billion |
| Growth Rate | CAGR of 12.8% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Treatment Type, Distribution Channel, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Rest of Latin America, Germany, United kingdom, France, Spain, Italy, Rest of Europe, India, Malaysia, Singapore, Thailand, Rest of South Asia, China, Japan, South Korea, Austria, New Zealand, GCC countries, South Africa, Israel, Rest of MEA |
| Key Companies Profiled | Acacia Pharma; Hoffmann-La Roche AG; Novartis AG; Ani Pharmaceuticals, Inc; Camurus AB; Sanofi S.A.; Helsinn Holding S.A.; Eisai Corporation; Merck and Co.; GlaxoSmithKline Corporation |
| Customization | Available Upon Request |
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 8: Latin America Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 11: Europe Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033
Table 12: Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 13: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: South Asia Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033
Table 15: South Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 16: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 17: East Asia Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033
Table 18: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 19: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 20: Oceania Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033
Table 21: Oceania Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 22: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 23: MEA Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033
Table 24: MEA Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Figure 1: Global Market Value (US$ Million) by Treatment Type, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 7: Global Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033
Figure 8: Global Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 9: Global Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 10: Global Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 11: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 12: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 13: Global Market Attractiveness by Treatment Type, 2023 to 2033
Figure 14: Global Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 15: Global Market Attractiveness by Region, 2023 to 2033
Figure 16: North America Market Value (US$ Million) by Treatment Type, 2023 to 2033
Figure 17: North America Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 22: North America Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033
Figure 23: North America Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 24: North America Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 28: North America Market Attractiveness by Treatment Type, 2023 to 2033
Figure 29: North America Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 30: North America Market Attractiveness by Country, 2023 to 2033
Figure 31: Latin America Market Value (US$ Million) by Treatment Type, 2023 to 2033
Figure 32: Latin America Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 37: Latin America Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033
Figure 38: Latin America Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 40: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 41: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 43: Latin America Market Attractiveness by Treatment Type, 2023 to 2033
Figure 44: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 46: Europe Market Value (US$ Million) by Treatment Type, 2023 to 2033
Figure 47: Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 52: Europe Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033
Figure 53: Europe Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 54: Europe Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 55: Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 56: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 57: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 58: Europe Market Attractiveness by Treatment Type, 2023 to 2033
Figure 59: Europe Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 60: Europe Market Attractiveness by Country, 2023 to 2033
Figure 61: South Asia Market Value (US$ Million) by Treatment Type, 2023 to 2033
Figure 62: South Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 63: South Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 64: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 65: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 66: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 67: South Asia Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033
Figure 68: South Asia Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 69: South Asia Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 70: South Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 71: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 72: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 73: South Asia Market Attractiveness by Treatment Type, 2023 to 2033
Figure 74: South Asia Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 75: South Asia Market Attractiveness by Country, 2023 to 2033
Figure 76: East Asia Market Value (US$ Million) by Treatment Type, 2023 to 2033
Figure 77: East Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 78: East Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 79: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 80: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 81: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 82: East Asia Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033
Figure 83: East Asia Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 84: East Asia Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 85: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 86: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 87: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 88: East Asia Market Attractiveness by Treatment Type, 2023 to 2033
Figure 89: East Asia Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 90: East Asia Market Attractiveness by Country, 2023 to 2033
Figure 91: Oceania Market Value (US$ Million) by Treatment Type, 2023 to 2033
Figure 92: Oceania Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 93: Oceania Market Value (US$ Million) by Country, 2023 to 2033
Figure 94: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 95: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 96: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 97: Oceania Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033
Figure 98: Oceania Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 99: Oceania Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 100: Oceania Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 101: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 102: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 103: Oceania Market Attractiveness by Treatment Type, 2023 to 2033
Figure 104: Oceania Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 105: Oceania Market Attractiveness by Country, 2023 to 2033
Figure 106: MEA Market Value (US$ Million) by Treatment Type, 2023 to 2033
Figure 107: MEA Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 108: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 109: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 110: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 111: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 112: MEA Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033
Figure 113: MEA Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 114: MEA Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 115: MEA Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 116: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 117: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 118: MEA Market Attractiveness by Treatment Type, 2023 to 2033
Figure 119: MEA Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 120: MEA Market Attractiveness by Country, 2023 to 2033
The market was valued at USD 1.04 billion in 2022.
The market is estimated to secure a valuation of USD 1.17 billion in 2023.
The market is forecast to register a CAGR of 12.8% through 2033.
An increasing number of surgeries drives growth in the PONV market.
Acacia Pharma, Hoffmann-La Roche AG, and Novartis AG are the key players in the market.
Explore Similar Insights
Postoperative Nausea and Vomiting (PONV) Management Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
